Atossa Genetics’ endoxifen programs are awaiting key catalysts in the coming year. Top-line data from a Phase II study in women with elevated mammographic breast density (MBD) is expected in Q219. The high rate of dropouts due to skin irritation/rashes may prompt a formulation change. The firm is also advancing an oral endoxifen formulation to reduce cancer cell activity in the window of opportunity between breast cancer diagnosis and surgery, and in women refractory to tamoxifen. Our r
09 May 2019
Atossa Genetics - Endoxifen catalysts expected in 2019
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Atossa Genetics - Endoxifen catalysts expected in 2019
Atossa Therapeutics, Inc. (ATOS:NAS) | 0 0 0.0%
- Published:
09 May 2019 -
Author:
Pooya Hemami -
Pages:
6
Atossa Genetics’ endoxifen programs are awaiting key catalysts in the coming year. Top-line data from a Phase II study in women with elevated mammographic breast density (MBD) is expected in Q219. The high rate of dropouts due to skin irritation/rashes may prompt a formulation change. The firm is also advancing an oral endoxifen formulation to reduce cancer cell activity in the window of opportunity between breast cancer diagnosis and surgery, and in women refractory to tamoxifen. Our r